ArticleFrontiers in pharmacology2022

Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment.

Yewon Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.